CIFR
Cipher Mining Inc.
There isn't enough reported data to score CIFR yet.
IVZ
Invesco Ltd.
IVZ lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
CIFR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| N/A | |
| N/A |
CIFR's revenue and profitability are currently weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like CIFR.
IVZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| N/A | |
| N/A |
IVZ's revenue is currently healthy, but its profitability is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IVZ.
CIFR PE Valuation
CIFR has no meaningful PE right now: it lost money over the past year.
IVZ PE Valuation
IVZ has no meaningful PE right now: it lost money over the past year.
CIFR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CIFR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
IVZ Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for IVZ, with profitability improving.
CIFR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.06 | -$2.86 |
| Q2 2026 | -$2.85 | -$2.40 |
| Q1 2026 | -$2.32 | -$1.94 |
| Q4 2025 | -$2.15 | -$2.01 |
| Q3 2025 | -$0.20 | -$0.07 |
| Q2 2025 | -$0.45 | -850% |
| Q1 2025 | -$0.38 | -733% |
| Q4 2024 | -$0.14 | -$0.04 |
IVZ has the stronger earnings trend. Trailing diluted EPS is down 1,630% for CIFR versus IVZ down 176%.
IVZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.15 | — |
| Q1 2025 | $1.25 | +$1.99 |
| Q4 2024 | $1.18 | +$1.91 |
| Q3 2024 | -$0.91 | -169% |
| Q2 2024 | -$0.74 | -152% |
| Q1 2024 | -$0.74 | -154% |
| Q4 2023 | -$0.73 | -149% |
| Q3 2023 | $1.31 | -34% |
| Q2 2023 | $1.41 | -39% |
IVZ is still losing money, but less than at its worst: $0.69 per share over the past year, against $0.91 at its worst in late 2024.
CIFR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $26.7M | -63% |
| Q2 2026 | $24.8M | -43% |
| Q1 2026 | $34.8M | -29% |
| Q4 2025 | $59.7M | +41% |
| Q3 2025 | $71.7M | +198% |
| Q2 2025 | $43.6M | +18% |
| Q1 2025 | $49M | +1.7% |
| Q4 2024 | $42.2M | -2.8% |
CIFR's revenue has slid since its 2025 peak: $27M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -269% | -217 points |
| Q2 2026 | -316% | -212 points |
| Q1 2026 | -329% | -251 points |
| Q4 2025 | -503% | -544 points |
| Q3 2025 | -52% | +327 points |
| Q2 2025 | -104% | -60 points |
| Q1 2025 | -78% | -175 points |
| Q4 2024 | 40% | +4 points |
CIFR's operating margin was −269% last quarter, down 217 points from the same quarter a year ago.
IVZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +14% |
| Q2 2026 | $1.8B | +20% |
| Q1 2026 | $1.7B | +14% |
| Q4 2025 | $1.7B | +6.2% |
| Q3 2025 | $1.6B | +8.2% |
| Q2 2025 | $1.5B | +2.2% |
| Q1 2025 | $1.5B | +3.7% |
| Q4 2024 | $1.6B | +13% |
IVZ has the edge over CIFR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +6.8 points |
| Q2 2026 | 20% | +5.8 points |
| Q1 2026 | 19% | +1 points |
| Q4 2025 | -86% | -106 points |
| Q3 2025 | 17% | +9.9 points |
| Q2 2025 | 14% | +0.2 points |
| Q1 2025 | 18% | +3.7 points |
| Q4 2024 | 20% | +96 points |
IVZ has the edge over CIFR on profitability, with a higher operating margin.
CIFR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7B | -$1.4B |
| Q2 2026 | -$653.8M | -$566.3M |
| Q1 2026 | -$462.5M | -$390.7M |
| Q4 2025 | -$280.3M | -$204.2M |
| Q3 2025 | -$256.2M | -$173.1M |
| Q2 2025 | -$87.5M | -$54.3M |
| Q1 2025 | -$71.8M | -$37.3M |
| Q4 2024 | -$76.1M | +$38M |
CIFR's free cash flow was −$3.1B over the past year, against −$492M the year before. Free cash flow isn't a meaningful measure for financial services companies like CIFR.
IVZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $442.8M | -24% |
| Q2 2026 | $703.7M | +33% |
| Q1 2026 | $198.4M | +$306.4M |
| Q4 2025 | $432.2M | +33% |
| Q3 2025 | $586.4M | +43% |
| Q2 2025 | $530.4M | +15% |
| Q1 2025 | -$108M | -$32.6M |
| Q4 2024 | $323.9M | -52% |
IVZ has the edge over CIFR on cash generation, producing positive trailing cash flow while its opponent burns cash.
CIFR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +30.3M shares |
| 1 year | +12% | +46.5M shares |
| 3 years | +75% | +188M shares |
| 5 years | +102% | +222M shares |
CIFR has 440M diluted shares, up 12% from a year ago, despite $151M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7M |
| Q2 2026 | $45.2M |
| Q1 2026 | $3.8M |
| Q4 2025 | $82.3M |
| Q3 2025 | $3M |
| Q2 2025 | $3.2M |
| Q1 2025 | $1.1M |
| Q4 2024 | $16.9M |
CIFR spent $151M buying back its own shares over the past year, about six times what it spent the year before.
IVZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.9M shares |
| 1 year | -0.5% | -2.1M shares |
| 3 years | -1.4% | -6.3M shares |
| 5 years | -2.9% | -13.7M shares |
| Available history | +2.7% | +12M shares |
IVZ has the edge over CIFR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $75M |
| Q2 2026 | $50.4M |
| Q1 2026 | $69.2M |
| Q4 2025 | $25.8M |
| Q3 2025 | $29.2M |
| Q2 2025 | $25.5M |
| Q1 2025 | $43.1M |
| Q4 2024 | $26M |
IVZ spent $220M buying back its own shares over the past year, up 78% from the year before.
CIFR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.3x | Net Cash |
| Q1 2025 | 125.4x | High |
| Q4 2024 | 0.5x | Very low |
| Q3 2024 | -0.7x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q2 2023 | -0.1x | Net Cash |
CIFR has the edge over IVZ on leverage, with a lower net debt burden relative to earnings.
IVZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | -0.1x | Net Cash |
| Q3 2023 | 0.2x | Very low |
| Q2 2023 | 0.4x | Very low |
| Q1 2023 | 0.5x | Very low |
| Q4 2022 | 0.0x | Very low |
IVZ's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like IVZ.
CIFR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 7.8 | Oversold |
CIFR's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
IVZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 11.7 | Oversold |
IVZ's weekly RSI is 48 (neutral) and its Stochastic is 12 (oversold).
CIFR PE vs Financial Services Sector
| Metric | CIFR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
CIFR has no meaningful PE right now: it lost money over the past year.
IVZ PE vs Financial Services Sector
| Metric | IVZ | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IVZ has no meaningful PE right now: it lost money over the past year.
CIFR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.6 | 33% below |
| 20 week MA | $15.5 | 54% below |
| 50 week MA | $17.0 | 58% below |
| 100 week MA | $12.2 | 41% below |
| 200 week MA | $7.86 | 9% below |
CIFR is in a downtrend: it's below all five of its weekly moving averages, and 9% below its 200-week average.
IVZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.2% below |
| 20 week MA | $30.0 | 5.2% below |
| 50 week MA | $27.8 | 2.3% above |
| 100 week MA | $23.2 | 23% above |
| 200 week MA | $19.7 | 45% above |
IVZ has the edge over CIFR on trend strength, trading above more of its moving averages.
CIFR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $9.95 | +0.3% |
| 2021 | $9.95 | $5.21 | -48% |
| 2022 | $5.21 | $0.54 | -90% |
| 2023 | $0.54 | $4.13 | +665% |
| 2024 | $4.13 | $4.86 | +18% |
| 2025 | $4.86 | $15.2 | +213% |
| 2026 YTD | $15.2 | $7.15 | -53% |
CIFR's yearly returns have swung widely, from +665% in 2023 to −90% in 2022. It's down 53% so far in 2026.
IVZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.8 | $17.6 | -1.2% |
| 2021 | $17.6 | $23.3 | +33% |
| 2022 | $23.3 | $18.4 | -21% |
| 2023 | $18.4 | $17.8 | -2.9% |
| 2024 | $17.8 | $17.7 | -0.9% |
| 2025 | $17.7 | $27.0 | +52% |
| 2026 YTD | $27.0 | $28.5 | +5.6% |
IVZ has the edge over CIFR on returns for 2026, with the stronger performance.